When I ask what might change beyond weight, sleep is one of the things I am interested in. But “sleep problems” covers more than one experience, and the medicine studied matters too.
Two 52-week trials tested tirzepatide in people with obesity and moderate-to-severe obstructive sleep apnoea — repeated interruptions to breathing during sleep. One trial included people not using positive airway pressure, or PAP, and the other included people who were.
In the first trial, the difference compared with placebo was about 20 fewer breathing events an hour. Stomach and bowel adverse events were the most common.
What does this leave open?
The medicine was tirzepatide, not semaglutide, the active ingredient in Ozempic. These were not trials of general insomnia or specifically of women going through menopause.
I would keep the result attached to that particular medicine and condition. It cannot answer every question about sleep, and changes to treatment, including PAP, need a clinical review.